Ectogenesis is the development of a fetus outside the human uterus, either partially or entirely, using artificial womb technology. The term was coined by British scientist J.B.S. Haldane in 1924, and while full ectogenesis from conception to birth remains theoretical, partial versions of the technology have already been tested in animal studies with promising results.
Partial vs. Complete Ectogenesis
There are two distinct forms of ectogenesis, and they represent very different levels of technological challenge. Partial ectogenesis refers to continuing the gestation of a fetus after it has been removed from a pregnant person’s body. This is essentially what neonatal intensive care does now, just pushed earlier. Complete ectogenesis would mean sustaining a fetus from its earliest stages all the way to term without ever being inside a human body. Complete ectogenesis remains firmly in the realm of science fiction for now.
The distinction matters because partial ectogenesis is where real progress is happening. The goal isn’t to replace pregnancy but to save extremely premature infants who currently have slim chances of survival.
How Artificial Womb Technology Works
Artificial womb systems try to recreate the conditions inside the uterus rather than treating a premature baby like a tiny adult who needs to breathe air. Traditional neonatal care forces underdeveloped lungs to inflate and exchange oxygen, which causes significant damage. Artificial wombs take the opposite approach: they keep the lungs filled with fluid, just as they would be in the womb, and oxygenate the blood through an umbilical connection instead.
Two main designs have emerged. In pumpless systems, the fetus’s own heart pushes blood through a low-resistance oxygenator connected to the umbilical cord, mimicking how blood naturally flows through the placenta. In pump-driven systems, a mechanical pump circulates oxygenated blood into the umbilical vein. Both configurations enclose the fetus in a sealed bag filled with synthetic amniotic fluid, a carefully formulated solution that matches the electrolyte balance, pH, albumin, and glucose levels of natural amniotic fluid. Researchers have found that using fluid closely matched to the real thing leads to healthier cell signaling and less tissue damage compared to standard medical fluids.
Where the Science Stands
The landmark moment came in 2017, when researchers at the Children’s Hospital of Philadelphia (CHOP) successfully kept premature lamb fetuses alive and developing in their “Biobag” system. The lambs were developmentally equivalent to human infants at 22 to 24 weeks of gestation, the very edge of what modern medicine can handle. They survived in the device for up to four weeks, and in some cases longer.
The results were striking. The lambs maintained stable blood pressure and normal oxygen levels. Their brains developed normally, their lungs matured, and the nerve fibers in their central nervous systems formed their protective insulation on schedule. Since that study, other research groups have built on and refined these systems, conducting further safety testing.
Earlier attempts were less successful. A separate system called the Ex-Vivo Uterine Environment (EVE) tested in premature lambs at roughly the same developmental stage managed an average survival of only about 27 hours, with most animals deteriorating before the study endpoint. That contrast illustrates how quickly the technology has advanced and how much design details matter.
Why Extremely Premature Infants Need This
Babies born before 28 weeks of gestation face enormous risks. In the 1990s, survival before 24 weeks was rare. Some hospitals now report survival rates above 50% at 22 weeks for infants who receive aggressive treatment, but survival alone doesn’t tell the full story. The gestation at which more than half of surviving infants are free from major disability is around 26 weeks. That leaves a gap of roughly four weeks where babies can be kept alive but face high rates of serious, lifelong complications affecting the brain, lungs, and eyes.
Artificial womb technology targets that gap. By keeping the fetus in a womb-like environment rather than forcing premature organ systems to function in open air, the idea is to let development continue as it would have naturally. The FDA has indicated it views these devices specifically as alternatives to existing care for extremely premature infants, not as tools for earlier intervention or complete gestation.
Barriers to Human Trials
Several major obstacles stand between animal success and human use. The umbilical blood vessels tend to spasm when disturbed, which can disrupt circulation through the device. Current systems can only replicate a limited set of placental functions, leaving open questions about proper nutrition, hormone delivery, and monitoring of organ development, particularly the brain and lungs. Researchers also need to manage fetal movement, which can destabilize blood flow through the circuit.
Perhaps the most fundamental concern is that nearly all testing has been done in sheep, and sheep fetuses differ from human fetuses in important ways. The developmental timelines of the fetal lung and brain are not identical between species, meaning the favorable outcomes seen in lambs may not translate directly to humans. Some researchers have cautioned that fetuses much below 20 weeks of gestation likely could not be supported on an artificial placenta at all, because their umbilical vessels would be too small and fragile for the necessary connections.
There are also questions no animal model can answer. We don’t fully understand how much a child’s psychological and neurological development depends on the sensory environment of the womb: the parent’s voice, heartbeat, movement, and hormonal signals. Isolation from that environment could carry developmental consequences that won’t become apparent until years after birth.
Legal and Ethical Complications
Ectogenesis creates legal puzzles that existing law wasn’t built to handle. In English law, and in most legal systems globally, legal personhood and its protections are assigned at birth. That framework assumes a clear boundary: a fetus is inside a body, and then it is born. An entity gestating inside a sealed bag connected to machines fits neither category neatly. Legal scholars have argued that the traditional concept of “born alive” no longer distinguishes between developing human beings in the way it was originally intended, and that reform is needed.
The stakes are high in both directions. The legal status given to a fetus in an artificial womb would determine what can and cannot be done to it, including whether it could be disconnected and under what circumstances. It would also affect the legal freedoms of the people who contributed genetic material or who were pregnant before transfer to the device.
The FDA has laid out strict conditions for any future human trial. Because an artificial womb trial would expose newborns to more than minimal risk, enrollment would need to offer a direct clinical benefit to each individual subject. The risk profile would have to be at least as favorable as standard intensive care for a baby of the same gestational age. And parental permission would be required. Before any trial could begin, researchers would need to demonstrate proof of concept through animal data and show that the device design is likely to produce the intended treatment effect over a long enough period to meaningfully improve outcomes.
What Full Ectogenesis Would Require
Growing a human from embryo to birth entirely outside the body remains far beyond current capabilities. The earliest weeks of development involve an intricate exchange between the embryo and the uterine lining, including implantation, formation of the placenta, and a cascade of hormonal signals that no machine can yet replicate. Even the most optimistic researchers describe a lower limit of around 20 weeks for artificial placenta support, which means the first half of gestation would still need to occur biologically.
Complete ectogenesis would require not just a fluid-filled bag and an oxygenator, but a synthetic system capable of performing every function of the placenta and uterus simultaneously: immune protection, waste removal, hormone regulation, nutrient delivery calibrated to each stage of development, and possibly sensory input that supports normal brain wiring. Each of those challenges is individually unsolved. Together, they place full ectogenesis in a fundamentally different category from the partial systems now being tested.